- Info
- Insider Trading
- Financials
- Holders: XFOR, XFOR
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR)
CUSIP: 98420X103
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 7,938,059
- Total 13F shares
- 653,289
- Share change
- -97,812,263
- Total reported value
- $1,241,249
- Price per share
- $1.90
- Number of holders
- 2
- Value change
- -$59,123,616
- Number of sells
- 90
Quarterly Holders Quick Answers
What is CUSIP 98420X103?
CUSIP 98420X103 identifies XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 98420X103:
Top shareholders of XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
213%
|
16,915,784
|
$3,998,891 | — | 31 Mar 2025 | |
| NEA Management Company, LLC |
13F
|
Company |
189%
|
14,986,793
|
$3,542,878 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
3%
from 13D/G
|
11,430,304
|
$2,702,123 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
13D/G
|
Company · The Vanguard Group |
4.8%
from 13D/G
|
8,067,516
|
$1,903,935 | — | 31 Mar 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
92%
|
7,310,650
|
$1,754,556 | — | 31 Mar 2025 | |
| KINGDON CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
88%
|
7,000,000
|
$1,654,800 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
13D/G
|
Company |
1.7%
from 13D/G
|
6,776,515
|
$1,601,968 | — | 31 Mar 2025 | |
| Paula Ragan |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
4,526,964
mixed-class rows
|
$1,515,173 | — | 12 Feb 2025 | |
| UBS Group AG |
13F
|
Company |
63%
|
5,037,183
|
$1,188,775 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
46%
|
3,619,682
|
$855,794 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
38%
|
3,055,081
|
$722,221 | — | 31 Mar 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
28%
|
2,235,655
|
$528,509 | — | 31 Mar 2025 | |
| Mary DiBiase |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
1,569,228
mixed-class rows
|
$518,005 | — | 12 Feb 2025 | |
| Pale Fire Capital SE |
13F
|
Company |
26%
|
2,035,362
|
$481,160 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
22%
|
1,712,361
|
$404,802 | — | 31 Mar 2025 | |
| Christophe Arbet-Engels |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
1,045,023
mixed-class rows
|
$392,350 | — | 12 Feb 2025 | |
| Adam S. Mostafa |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
1,373,414
mixed-class rows
|
$385,900 | — | 12 Feb 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
16%
|
1,253,815
|
$296,402 | — | 31 Mar 2025 | |
| CIBC WORLD MARKET INC. |
13F
|
Company |
0.44%
|
35,000
|
$248,220 | — | 31 Mar 2025 | |
| Arthur Taveras |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
816,274
mixed-class rows
|
$218,459 | — | 04 Oct 2024 | |
| AXA S.A. |
13F
|
Company |
8.7%
|
691,116
|
$163,382 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
8.2%
|
650,000
|
$153,660 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
7.2%
|
570,011
|
$134,751 | — | 31 Mar 2025 | |
| Derek M. Meisner |
3/4/5
|
Chief Legal Officer |
—
class O/S missing
|
145,155
|
$130,640 | — | 17 Aug 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
6.1%
|
481,528
|
$113,833 | — | 31 Mar 2025 | |
| Diego Cadavid |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
104,107
|
$93,696 | — | 01 Mar 2022 | |
| Alison Frances Lawton |
3/4/5
|
Director |
—
class O/S missing
|
96,667
|
$85,241 | — | 10 Jun 2024 | |
| William Aliski |
3/4/5
|
Director |
—
class O/S missing
|
96,667
|
$85,241 | — | 10 Jun 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
4.3%
|
344,746
|
$81,497 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
4.2%
|
335,436
|
$79,296 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
3.5%
|
273,865
|
$64,742 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
3.4%
|
267,628
|
$64,230 | — | 31 Mar 2025 | |
| Mark Baldry |
3/4/5
|
Chief Commercial Officer |
0.32%
|
25,337
|
$62,886 | — | 16 May 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
3.3%
|
258,759
|
$61,171 | — | 31 Mar 2025 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
3.2%
|
252,602
|
$59,614 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
2.4%
|
188,415
|
$44,454 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
2.3%
|
185,083
|
$43,753 | — | 31 Mar 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
2.2%
|
172,108
|
$40,686 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
2.1%
|
165,438
|
$39,110 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
1.5%
|
122,362
|
$28,926 | — | 31 Mar 2025 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
1.4%
|
111,704
|
$26,000 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.4%
|
109,570
|
$25,902 | — | 31 Mar 2025 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
1.3%
|
100,693
|
$23,804 | — | 31 Mar 2025 | |
| SG Americas Securities, LLC |
13F
|
Company |
1.2%
|
91,487
|
$22,000 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.1%
|
86,963
|
$20,558 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.1%
|
83,015
|
$20,000 | — | 31 Mar 2025 | |
| Corebridge Financial, Inc. |
13F
|
Company |
1.1%
|
83,602
|
$19,764 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
1%
|
81,536
|
$19,275 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.97%
|
77,340
|
$18,252 | — | 31 Mar 2025 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.95%
|
75,550
|
$17,858 | — | 31 Mar 2025 |
Institutional Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q2 2025
As of 30 Jun 2025,
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) was held by
2 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
653,289 shares.
The largest 2 holders included
NEA Management Company, LLC and ACORN CAPITAL ADVISORS, LLC.
This page lists
2
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
91
Q2 2025 holders
2
Holder diff
-89
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.